publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
vaccin
recombin
secret
protein
helminth
onchocerca
volvulu
potent
adjuv
induc
antibodi
ovalbumin
studi
adjuvant
recombin
onchocerca
volvulu
activ
associ
ovalbumin
ova
mice
singl
immun
one
boost
exceed
efficaci
alum
mpl
tdm
adjuv
term
endpoint
total
igg
antiova
titr
use
helminthderiv
adjuv
igg
isotyp
respons
ova
mix
profil
spleen
cell
cytokin
exclus
potent
adjuvant
confirm
mice
vaccin
peptid
protein
sarscov
chimer
polypeptid
antigen
unusu
helminth
product
adjuv
augment
also
respons
latter
properti
potenti
util
stimul
antivir
immun
respons
filari
nematod
longliv
parasit
human
host
exampl
onchocerca
volvulu
worm
live
year
use
larg
armouri
immunoregulatori
molecul
subvert
protect
immun
respons
host
minim
sever
patholog
helminthderiv
modul
human
immun
respons
great
potenti
new
therapeut
exampl
secret
glycoprotein
product
rodent
filari
nematod
acanthocheilonema
vitea
broadli
antiinflammatori
properti
inhibit
cytokin
product
experiment
induc
arthriti
mice
current
develop
novel
antiinflammatori
therapeut
anoth
nematod
bodi
fluid
pig
roundworm
ascari
suum
contain
potent
activ
stimul
characterist
regulatori
cell
parasit
product
reduc
inflamm
caus
experiment
induc
delay
type
hypersensit
mice
two
helminth
product
also
report
act
adjuv
strong
induc
respons
bystand
protein
vaccin
particular
protein
secret
adult
nippostrongylu
brasiliensi
parasit
rodent
found
strong
induc
respons
mice
immun
unrel
protein
hen
egg
lysozym
similarli
lactonfucopentaos
iii
carbohydr
found
surfac
egg
human
parasit
schistosoma
mansoni
act
adjuv
bystand
protein
human
serum
albumin
inject
intranas
subcutan
intraperitoneali
mice
activationassoci
secret
protein
asp
parasit
nematod
highli
immunogen
studi
potenti
vaccin
compon
particularli
hookworm
asp
conduct
experi
design
evalu
recombin
onchocerca
volvulu
possibl
vaccin
candid
onchocerciasi
human
vaccin
mice
recombin
protein
alon
alum
freund
adjuv
measur
isotyp
broadli
associ
cell
respons
respect
stimul
antibodi
respons
protein
slight
domin
sinc
effect
occur
vaccin
mice
absenc
adjuv
ask
question
whether
protein
could
act
adjuv
assist
unrel
protein
induc
antibodi
respons
present
studi
purifi
product
helminth
found
strong
induc
exclus
respons
recombin
protein
express
histidinetag
protein
e
coli
use
ptrchi
express
vector
invitrogen
carlsbad
ca
inclus
bodi
contain
insolubl
treat
urea
c
overnight
ureasolubl
purifi
prepar
sdspage
prepcel
biorad
hercul
ca
proteincontain
fraction
elut
laemmli
buffer
mm
tri
mm
glycin
sd
ph
analyz
sdspage
fraction
contain
purifi
identifi
india
tm
hisprobehrp
pierc
rockford
il
chemiluminesc
western
blot
protein
concentr
determin
use
detergentcompat
protein
assay
reagent
biorad
although
protein
work
dilut
test
neg
bacteri
endotoxin
use
limulu
amoebocyt
lysat
assay
sigma
st
loui
mo
sent
sampl
quantit
lp
test
follow
fda
guidelin
cambrex
bio
scienc
baltimor
md
test
reveal
residu
endotoxin
unit
eu
g
protein
dose
gmous
therefor
anim
would
receiv
eu
per
inject
well
fda
accept
limit
euml
biolog
howev
definit
exclud
possibl
residu
lp
contribut
adjuv
effect
batchtreat
concentr
stock
solut
mgml
three
time
lpsremov
gel
detoxigel
tm
system
pierc
biotechnolog
rockford
il
adjust
protein
concentr
accordingli
repeat
test
cambrex
show
detect
lp
treat
prepar
singl
batch
use
throughout
experi
present
first
use
ovalbumin
ova
sigma
grade
v
model
antigen
stimul
appreci
antibodi
respons
inject
mice
without
adjuv
peptid
deriv
spike
protein
sarsassoci
coronaviru
sarscov
design
synthes
standard
solidphas
fmoc
method
microchemistri
laboratori
new
york
blood
center
span
amino
acid
heptad
repeat
region
sarscov
protein
play
import
role
fusion
viru
target
cell
membran
flsc
polypeptid
chimera
fulllength
bal
first
second
extracellular
domain
solubl
join
acid
linker
polypeptid
faith
duplic
structur
function
antigen
properti
nativ
complex
intermedi
aris
hiv
replic
enabl
bind
target
cell
flsc
inhibit
bind
vitro
target
cell
express
therefor
antibodi
direct
flsc
may
block
bind
plasmid
express
flsc
protein
kindli
provid
dr
pinter
public
health
research
institut
permiss
dr
al
devico
univers
maryland
stabl
cell
line
express
recombin
flsc
establish
transfect
plasmid
cell
use
fugen
boehring
mannheim
indianapoli
accord
manufactur
protocol
solubl
flsc
purifi
cell
cultur
medium
lectin
chromatographi
galanthu
nivali
snowdrop
agglutinin
sigmaaldrich
st
loui
mo
describ
procedur
deal
mice
approv
institut
anim
care
use
committe
new
york
blood
center
use
male
balbccbyj
mice
charl
river
laboratori
inc
wilmington
immun
commerci
adjuv
alum
sigma
mpl
tdm
sigma
use
control
test
adjuv
mpl
tdm
equival
ribi
tm
adjuv
compos
equal
amount
monophosphoryl
lipid
detoxifi
endotoxin
minnesota
mpl
synthet
trehalos
dicorynomycol
tdm
oil
squalen
tween
per
immun
anim
receiv
g
antigen
ova
flsc
ml
steril
lpsfree
phosphatebuff
salin
pb
mix
one
commerci
adjuv
follow
manufactur
instruct
ml
pb
antigenadjuv
mixtur
adjuv
control
inject
group
five
mice
subcutan
nape
neck
mice
receiv
one
boost
ova
two
boost
flsc
day
postimmun
experi
perform
twice
repres
data
shown
mice
bled
retroorbit
prior
vaccin
establish
antibodi
baselin
ten
day
final
vaccin
mice
euthan
bled
total
igg
igg
isotyp
antibodi
respons
antigen
measur
elisa
ninetysixwel
vinyl
elisa
plate
costar
biorad
hercul
ca
coat
overnight
c
lwell
ova
gml
gml
flsc
gml
carbon
coat
buffer
ph
wash
five
time
plate
block
l
nonfat
milk
powder
pb
h
c
mous
sera
serial
dilut
pb
ad
lwell
follow
incub
h
c
extens
wash
goat
antimous
igg
antibodi
sigma
ad
dilut
lwell
h
c
igg
isotyp
biotinyl
rabbit
antigoat
igg
extravidin
peroxidas
conjug
sigma
dilut
h
c
ad
sequenti
final
wash
step
l
tmb
sigma
ad
reaction
stop
equal
volum
h
absorb
nm
measur
spectramax
elisa
reader
molecular
devic
sunnyval
ca
serum
antibodi
titr
determin
measur
last
dilut
elisa
result
sd
appropri
control
treatment
optic
densiti
od
serum
mous
titrat
mean
titr
treatment
group
present
exsanguin
mice
anaesthesia
spleen
remov
cut
two
piec
steril
scissor
made
singl
cell
suspens
use
steril
glass
potterelvehjem
tissu
grinder
fisher
scientif
intern
pittsburgh
pa
cell
suspens
pass
steril
dispos
cell
strainer
falcon
brand
bd
bioscienc
bedford
cell
wash
three
time
rpmi
supplement
heatinactiv
foetal
bovin
serum
fb
mm
hepe
buffer
mm
lglutamin
uml
penicillin
gml
streptomycin
sigma
cell
count
viabil
alway
cultur
rpmi
fb
quadrupl
well
per
well
roundbottom
cultur
plate
nunc
brand
fisher
scientif
h
c
humidifi
co
incub
spleen
cell
cultur
medium
alon
optim
concentr
ova
gml
pha
pma
antimous
bd
bioscienc
posit
control
stimuli
supernat
collect
h
assay
mous
use
elisa
assay
quantikin
brand
r
system
minneapoli
mn
accord
manufactur
protocol
order
evalu
possibl
contribut
small
amount
residu
lp
adjuv
effect
compar
adjuvant
work
dilut
batch
either
untreat
batch
treat
three
time
lpsremov
gel
fig
uppermost
line
show
treat
recombin
protein
perform
better
untreat
protein
augment
antibodi
respons
ova
immun
mice
mean
antiova
titr
obtain
use
treat
adjuv
compar
use
untreat
batch
respect
could
therefor
rule
lp
contribut
factor
adjuv
properti
recombin
protein
sinc
better
adjuv
use
lp
remov
geltreat
batch
experi
use
gmous
protein
much
potent
enhanc
antibodi
product
commerci
adjuv
alum
mpl
tdm
fig
even
though
endpoint
titr
use
lower
experi
shown
fig
data
fig
still
higher
achiev
use
adjuv
antiova
reciproc
endpoint
titr
use
adjuv
titr
obtain
use
mpl
tdm
alum
adjuv
respect
titr
consider
lower
adjuv
induc
appreci
antiova
titr
detect
ige
antibodi
ova
spleen
cell
mice
receiv
ova
show
exclus
cytokin
profil
restimul
ova
vitro
fig
contrast
respons
use
alum
adjuv
sole
natur
mpl
tdm
adjuv
result
mix
respons
ifn
immun
antigen
unabl
measur
appreci
amount
supernat
mous
spleen
cell
cultur
except
posit
controltr
pma
cultur
shown
act
better
adjuv
alum
mpl
tdm
stimul
product
antibodi
ova
test
protein
similar
adjuv
potenc
antigen
deriv
human
pathogen
name
sarscov
immun
balbccbyj
mice
use
batch
lpsneg
mix
g
sarscov
peptid
flsc
polypeptid
instead
ova
immun
mice
given
two
boost
time
optim
respons
small
peptid
ie
total
three
inject
flsc
test
adjuv
mpl
tdm
control
use
ova
control
antigen
endpoint
titr
mpl
tdm
use
adjuv
respect
total
igg
titr
approxim
time
higher
previou
experi
suggest
addit
boost
significantli
enhanc
antibodi
product
adjuvant
peptid
exceed
mpl
tdm
judg
endpoint
igg
titr
versu
respect
fig
antiflsc
endpoint
igg
titr
achiev
use
adjuv
equival
approxim
fig
igg
isotyp
respons
peptid
flsc
polypeptid
summar
tabl
protein
stimul
higher
titr
mpl
tdm
titr
equal
low
use
adjuv
titr
polypeptid
consider
lower
peptid
mpl
tdm
induc
higher
titr
flsc
wherea
titr
use
endpoint
titr
mean
five
mice
per
group
adjuv
strike
differ
mpl
tdminduc
respons
lack
respons
use
mpl
tdm
eightfold
higher
respons
use
rather
mpl
tdm
adjuv
fourfold
higher
respons
flsc
adjuv
compar
mpl
tdm
contrast
flsc
antigen
antibodi
ova
detect
use
either
mpl
tdm
adjuv
data
shown
adjuvantantigen
model
perform
differ
depend
domin
antibodi
flsc
formul
either
adjuv
howev
either
antigen
respons
alway
higher
use
adjuv
flsc
immunogen
switch
antibodi
ribi
adjuv
favour
ribi
enhanc
ige
detect
use
adjuv
igm
iga
test
member
famili
protein
found
freeliv
parasit
nematod
nativ
protein
locat
secretori
granul
glandular
oesophagu
infect
thirdstag
larva
volvulu
recombin
protein
predict
molecular
weight
kd
also
angiogen
activ
mice
hookworm
homologu
shown
promis
vaccin
candid
yeastexpress
recombin
protein
formul
quil
adjuv
brenntag
biosector
frederikssund
denmark
hamster
studi
clearli
shown
discov
new
helminthderiv
adjuv
highli
effect
elicit
antibodi
respons
mice
immun
unrel
protein
polypeptid
peptid
antigen
furthermor
parasit
protein
exceed
adjuvant
alum
mpl
tdm
adjuv
especi
induct
associ
isotyp
studi
use
subcutan
rout
immun
balbccbyj
micea
strain
tend
respons
fact
induc
respons
strain
mpl
tdm
encourag
us
investig
whether
could
obtain
similar
result
mous
strain
recent
preliminari
studi
use
ovaimmun
mice
favour
respons
adjuv
associ
antibodi
respons
ova
also
consider
titr
antibodi
respons
ova
balbc
mice
data
present
also
signific
compon
thu
adjuv
augment
antibodi
respons
mice
overal
balanc
depend
genet
background
immun
anim
use
rang
dose
adjuv
gmous
significantli
activ
antibodi
respons
gmous
gave
adjuvant
intermedi
final
dose
chose
gmous
mice
toler
immun
overt
sign
toxic
investig
cell
respons
might
associ
high
antibodi
titr
look
cytokin
secret
spleen
cell
mice
immun
ova
adjuv
recal
cytokin
respons
ova
mice
immun
ova
adjuv
strongli
fig
unclear
adjuv
result
exclus
cytokin
respons
splenocyt
ovavaccin
mice
fig
mix
serum
antibodi
respons
fig
possibl
cytokin
profil
drain
lymph
node
cell
might
close
reflect
antibodi
phenotyp
antibodi
cytokin
respons
tempor
dissoci
abil
stimul
cellular
respons
unusu
helminth
protein
highli
express
infect
volvulu
thirdstag
larva
precis
role
invas
process
known
earli
human
respons
first
exposur
live
brugia
malayi
anoth
filari
nematod
recent
shown
number
cell
express
gmcsf
increas
exposur
vitro
cell
express
cytokin
possibl
asp
involv
stimul
cytokin
support
found
potent
stimul
cytokin
gmcsf
human
pbmc
unpublish
data
mechan
respons
adjuvant
yet
clear
howev
studi
use
human
pbmc
know
protein
bind
subpopul
monocyt
possibl
exert
direct
activ
effect
antigenpres
cell
current
investig
potenti
role
tolllik
receptor
bind
abl
detect
neutral
activ
serum
mice
vaccin
flsc
either
mpl
tdm
adjuv
separ
studi
mice
immun
purifi
flsc
develop
high
antibodi
titr
immunogen
none
sera
possess
neutral
activ
hiv
viru
vitro
author
suggest
major
portion
antibodi
respons
flsc
protein
may
direct
immunodomin
conform
epitop
uniqu
fusion
polypeptid
mediat
viral
neutral
present
studi
serum
flsc
adjuvantimmun
mice
also
recogn
protein
elisa
mean
total
igg
titr
obtain
mpl
tdm
adjuv
data
shown
titr
lower
flsc
sinc
epitop
may
access
flsc
fusion
polypeptid
safeti
regulatori
reason
current
abl
assess
neutral
activ
sarscov
conclus
shown
secret
protein
volvulu
infect
larva
act
potent
adjuv
bystand
protein
polypeptid
peptid
antigen
exceed
respons
induc
commerci
produc
alum
mpl
tdm
adjuv
unusu
helminth
protein
antibodi
cellular
respons
induc
strong
compon
depend
immunogen
adjuv
result
domin
antibodi
respons
lack
ige
immunostimulatori
helminth
protein
may
util
human
therapeut
